|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO
|
Bupivacaine results in increased expression of BAX protein 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of BAX protein]; [Glucose co-treated with Bupivacaine] results in increased expression of BAX protein; SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of BAX protein]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of BAX protein]]
|
CTD |
PMID:31672611 PMID:38487884 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of BCL2 protein 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein]; [Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]; SPHK2 protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]]
|
CTD |
PMID:31672611 PMID:34793778 PMID:38487884 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions decreases expression
|
ISO
|
MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]; MIR497 mRNA inhibits the reaction [SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; NLRX1 protein affects the reaction [MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of BDNF mRNA]
|
CTD |
PMID:35410500 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Casp3
|
caspase 3
|
decreases expression increases activity multiple interactions increases cleavage increases expression
|
ISO EXP
|
Bupivacaine results in decreased expression of CASP3 protein Bupivacaine results in increased activity of CASP3 protein MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]; SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of CASP3 protein]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of CASP3 protein]]
|
CTD |
PMID:16109997 PMID:20194319 PMID:38316350 PMID:38487884 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
decreases expression increases cleavage multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of CASP9 protein Bupivacaine results in increased cleavage of CASP9 protein MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]
|
CTD |
PMID:20194319 PMID:38316350 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cs
|
citrate synthase
|
decreases activity
|
EXP
|
Bupivacaine results in decreased activity of CS protein
|
CTD |
PMID:20645041 |
|
NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
multiple interactions
|
EXP
|
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA
|
CTD |
PMID:22341215 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Dnm1l
|
dynamin 1-like
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of DNM1L protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of DNM1L protein]
|
CTD |
PMID:34793778 |
|
NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420
|
|
G
|
Entpd4
|
ectonucleoside triphosphate diphosphohydrolase 4
|
multiple interactions
|
EXP
|
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of ENTPD4 mRNA
|
CTD |
PMID:22341215 |
|
NCBI chr15:51,040,665...51,068,450
Ensembl chr15:51,040,673...51,068,441
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions increases expression
|
ISO
|
Glucose promotes the reaction [Bupivacaine results in increased expression of H2AX protein]
|
CTD |
PMID:31672611 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hpgds
|
hematopoietic prostaglandin D synthase
|
increases expression
|
ISO
|
Bupivacaine results in increased expression of HPGDS mRNA; Bupivacaine results in increased expression of HPGDS protein
|
CTD |
PMID:19359520 |
|
NCBI chr 4:95,698,265...95,727,733
Ensembl chr 4:95,702,392...95,938,501
|
|
G
|
Hrh1
|
histamine receptor H 1
|
affects binding
|
ISO
|
HRH1 protein binds to Bupivacaine
|
CTD |
PMID:32061592 |
|
NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:149,120,039...149,208,248
|
|
G
|
Hspa12a
|
heat shock protein family A (Hsp70) member 12A
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of HSPA12A protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of DNM1L protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of MFN1 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PINK1 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PPARGC1A protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PRKN protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A1 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A4 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of TOMM20 protein]
|
CTD |
PMID:34793778 |
|
NCBI chr 1:267,921,780...268,083,171
Ensembl chr 1:267,921,782...268,082,794
|
|
G
|
Itgam
|
integrin subunit alpha M
|
increases expression multiple interactions
|
ISO
|
Bupivacaine results in increased expression of ITGAM mRNA 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Bupivacaine results in increased expression of ITGAM mRNA]
|
CTD |
PMID:19359520 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
G
|
Kcne1
|
potassium voltage-gated channel subfamily E regulatory subunit 1
|
multiple interactions
|
ISO
|
Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine]
|
CTD |
PMID:16931984 |
|
NCBI chr11:45,066,875...45,080,024
Ensembl chr11:45,064,162...45,081,247
|
|
G
|
Kcnk9
|
potassium two pore domain channel subfamily K member 9
|
multiple interactions
|
ISO
|
Bupivacaine inhibits the reaction [KCNK9 protein results in increased transport of Potassium]
|
CTD |
PMID:11249964 |
|
NCBI chr 7:106,316,783...106,362,452
Ensembl chr 7:106,326,684...106,361,921
|
|
G
|
Kcnn2
|
potassium calcium-activated channel subfamily N member 2
|
affects response to substance decreases activity
|
ISO
|
KCNN2 protein affects the susceptibility to Bupivacaine Bupivacaine results in decreased activity of KCNN2 protein
|
CTD |
PMID:32909839 PMID:33887967 |
|
NCBI chr18:40,004,693...40,445,043
Ensembl chr18:40,155,939...40,445,045
|
|
G
|
Kcnq1
|
potassium voltage-gated channel subfamily Q member 1
|
multiple interactions decreases activity increases response to substance
|
ISO
|
Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine] Bupivacaine results in decreased activity of KCNQ1 protein
|
CTD |
PMID:16931984 |
|
NCBI chr 1:207,721,134...208,054,073
Ensembl chr 1:207,721,131...208,054,072
|
|
G
|
Ldha
|
lactate dehydrogenase A
|
increases secretion multiple interactions increases expression
|
ISO
|
Bupivacaine results in increased secretion of LDHA protein notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased secretion of LDHA protein]; SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of LDHA protein]
|
CTD |
PMID:38316350 PMID:38487884 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Bupivacaine results in increased phosphorylation of MAPK1 protein Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:34060177 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Bupivacaine results in increased phosphorylation of MAPK3 protein Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:34060177 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mcl1
|
MCL1 apoptosis regulator, BCL2 family member
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of MCL1 protein MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]
|
CTD |
PMID:38316350 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782
|
|
G
|
Mfn1
|
mitofusin 1
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of MFN1 protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of MFN1 protein]
|
CTD |
PMID:34793778 |
|
NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190
|
|
G
|
Mir497
|
microRNA 497
|
multiple interactions increases expression
|
ISO
|
MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]; MIR497 mRNA inhibits the reaction [SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; MIR497 mRNA promotes the reaction [Bupivacaine results in decreased expression of NLRX1 mRNA]; NLRX1 protein affects the reaction [MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; SNHG12 inhibits the reaction [Bupivacaine results in increased expression of MIR497 mRNA]
|
CTD |
PMID:35410500 |
|
NCBI chr10:55,450,171...55,450,239
Ensembl chr10:55,450,162...55,450,241
|
|
G
|
Myf5
|
myogenic factor 5
|
decreases expression
|
EXP
|
Bupivacaine results in decreased expression of MYF5 protein
|
CTD |
PMID:10434046 |
|
NCBI chr 7:44,689,407...44,692,638
Ensembl chr 7:44,689,407...44,692,638
|
|
G
|
Myod1
|
myogenic differentiation 1
|
decreases expression
|
EXP
|
Bupivacaine results in decreased expression of MYOD1 protein
|
CTD |
PMID:10434046 |
|
NCBI chr 1:106,021,161...106,023,871
Ensembl chr 1:106,021,161...106,023,871
|
|
G
|
Myog
|
myogenin
|
decreases expression
|
EXP
|
Bupivacaine results in decreased expression of MYOG protein
|
CTD |
PMID:10434046 |
|
NCBI chr13:48,297,476...48,300,065
Ensembl chr13:48,297,235...48,300,065
|
|
G
|
Nlrx1
|
NLR family member X1
|
multiple interactions decreases expression
|
ISO
|
MIR497 mRNA promotes the reaction [Bupivacaine results in decreased expression of NLRX1 mRNA]; NLRX1 protein affects the reaction [MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of NLRX1 mRNA]
|
CTD |
PMID:35410500 |
|
NCBI chr 8:53,486,866...53,503,498
Ensembl chr 8:53,486,867...53,503,523
|
|
G
|
Pink1
|
PTEN induced kinase 1
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of PINK1 protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PINK1 protein]
|
CTD |
PMID:34793778 |
|
NCBI chr 5:155,813,838...155,825,950
Ensembl chr 5:155,813,838...155,825,950
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
increases expression decreases expression multiple interactions
|
ISO
|
Bupivacaine results in increased expression of PPARGC1A mRNA Bupivacaine results in decreased expression of PPARGC1A protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PPARGC1A protein]
|
CTD |
PMID:34793778 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
G
|
Prkcb
|
protein kinase C, beta
|
multiple interactions
|
EXP
|
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of PRKCB mRNA
|
CTD |
PMID:22341215 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740
|
|
G
|
Prkn
|
parkin RBR E3 ubiquitin protein ligase
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of PRKN protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PRKN protein]
|
CTD |
PMID:34793778 |
|
NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:51,210,330...52,430,304
|
|
G
|
Ptgdr
|
prostaglandin D2 receptor
|
affects expression
|
ISO
|
Bupivacaine affects the expression of PTGDR mRNA
|
CTD |
PMID:19359520 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
increases expression
|
ISO
|
Bupivacaine results in increased expression of PTGS1 mRNA
|
CTD |
PMID:18165598 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression multiple interactions
|
ISO
|
Bupivacaine results in increased expression of PTGS2 mRNA [Bupivacaine results in increased expression of PTGS2] which results in increased abundance of Dinoprostone
|
CTD |
PMID:18165598 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Slc25a29
|
solute carrier family 25 member 29
|
multiple interactions decreases activity
|
EXP
|
Emulsions inhibits the reaction [Bupivacaine results in decreased activity of SLC25A29 protein]
|
CTD |
PMID:35135371 |
|
NCBI chr 6:133,506,403...133,517,322
Ensembl chr 6:133,506,331...133,517,827
|
|
G
|
Slc2a1
|
solute carrier family 2 member 1
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of SLC2A1 protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A1 protein]
|
CTD |
PMID:34793778 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
G
|
Slc2a4
|
solute carrier family 2 member 4
|
multiple interactions decreases expression
|
ISO
|
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A4 protein]
|
CTD |
PMID:34793778 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
G
|
Slc6a2
|
solute carrier family 6 member 2
|
multiple interactions
|
ISO
|
Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]
|
CTD |
PMID:16725121 |
|
NCBI chr19:30,183,289...30,228,292
Ensembl chr19:30,183,383...30,223,348
|
|
G
|
Sphk2
|
sphingosine kinase 2
|
decreases expression decreases methylation multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of SPHK2 mRNA; Bupivacaine results in decreased expression of SPHK2 protein Bupivacaine results in decreased methylation of SPHK2 mRNA SPHK2 protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]; SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of BAX protein]; SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of CASP3 protein]; SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of LDHA protein]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of BAX protein]]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of CASP3 protein]]
|
CTD |
PMID:38487884 |
|
NCBI chr 1:105,317,332...105,324,985
Ensembl chr 1:105,317,333...105,321,637
|
|
G
|
Tomm20
|
translocase of outer mitochondrial membrane 20
|
decreases expression multiple interactions
|
ISO
|
Bupivacaine results in decreased expression of TOMM20 protein HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of TOMM20 protein]
|
CTD |
PMID:34793778 |
|
NCBI chr19:71,822,429...71,832,420
Ensembl chr19:71,822,411...71,832,510
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
increases activity multiple interactions
|
EXP
|
Bupivacaine results in increased activity of TRPV1 protein Bupivacaine affects the reaction [Capsaicin results in increased activity of TRPV1 protein]
|
CTD |
PMID:15854744 PMID:18172555 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
G
|
Xrcc6
|
X-ray repair cross complementing 6
|
increases expression multiple interactions
|
ISO
|
Bupivacaine results in increased expression of XRCC6 protein 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one inhibits the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein]; [Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein; Glucose inhibits the reaction [Bupivacaine results in increased expression of XRCC6 protein]
|
CTD |
PMID:31672611 |
|
NCBI chr 7:115,423,026...115,443,884
Ensembl chr 7:115,422,662...115,443,884
|
|
G
|
Ythdf1
|
YTH N6-methyladenosine RNA binding protein F1
|
multiple interactions decreases expression
|
ISO
|
YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of BAX protein]]; YTHDF1 protein promotes the reaction [SPHK2 protein inhibits the reaction [Bupivacaine results in increased expression of CASP3 protein]] Bupivacaine results in decreased expression of YTHDF1 protein
|
CTD |
PMID:38487884 |
|
NCBI chr 3:188,402,228...188,417,740
Ensembl chr 3:188,402,231...188,417,740
|
|
|
G
|
Slc25a29
|
solute carrier family 25 member 29
|
multiple interactions decreases activity
|
EXP
|
Emulsions inhibits the reaction [Levobupivacaine results in decreased activity of SLC25A29 protein]
|
CTD |
PMID:35135371 |
|
NCBI chr 6:133,506,403...133,517,322
Ensembl chr 6:133,506,331...133,517,827
|
|